Transgenomic to Acquire Clinical Data's Genetic Test Business for $15.4M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic has signed a definitive agreement to acquire the genetic testing business of Clinical Data for approximately $15.4 million, the firms announced after the close of the market Monday.

The acquisition will provide Transgenomic with Clinical Data's portfolio of Familion genetic tests for cardiac syndromes and PGxPredict tests for predicting drug response, which are currently sold by its PGx Health division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.